Ortivus (ORTI) Q1 2025 earnings summary

Executive summary

• Net sales decreased by 18% to SEK 18.1 million compared to the same quarter last year, with a gross margin increase to 42% from 41%.

• EBITDA was SEK -1.1 million, and net result after tax was SEK -2.5 million, both slightly worse than the previous year.

• Cash flow from operating activities improved to SEK -4.8 million from SEK -6.4 million year-over-year.

• Strategic focus on digitalization and internationalization, with new contracts and product rollouts in the UK and Estonia.

• Participation in international user forums and ongoing investments in iOS and cloud-based solutions.

Financial highlights

• Net sales: SEK 18.1 million (SEK 22.1 million Q1 2024), down 18% year-over-year.

• Gross margin: 42% (41% Q1 2024); adjusted gross margin also 42%.

• EBITDA: SEK -1.1 million (SEK -1.0 million Q1 2024); adjusted EBITDA unchanged.

• Net result after tax: SEK -2.5 million (SEK -2.2 million Q1 2024).

• Earnings per share: SEK -0.06 (SEK -0.05 Q1 2024).

• Cash flow from operations: SEK -4.8 million (SEK -6.4 million Q1 2024).

Outlook and guidance

• No formal forecasts provided; management highlights ongoing market challenges and opportunities in digital healthcare transformation.

• Continued investment in product development, especially iOS and cloud solutions, expected throughout 2025.